ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "comparative effectiveness"

  • Abstract Number: 2024 • ACR Convergence 2024

    Serum Urate Change Among Patients with Gout Treated with Anti-Hypertensive Medications: A Comparative Effectiveness Analysis

    Chio Yokose1, saiajay chigurupati2, Bohang Jiang2, Kiara Tan2, Natalie McCormick2 and Hyon K. Choi3, 1Massachusetts General Hospital, Waltham, MA, 2Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital, Lexington, MA

    Background/Purpose: Hypertension is the most common comorbidity among patients with gout, with a prevalence of nearly 75% among patients with gout. Losartan and calcium channel…
  • Abstract Number: 2075 • ACR Convergence 2024

    A Retrospective Cohort Study Assessing Outcomes and Safety in Patients Receiving Low Dose vs High Dose Cyclophosphamide in Myositis Interstitial Lung Disease (ILD)

    Saadia Sasha Ali1, Alexandra Lawrence2, Katie Bechman3, Amit Patel4, Surinder biring3, Sophia Steer4, Arti Mahto5, Catherine Myall4, Louise Pollard6, Marium Naqvi4, Amelia Holloway4, Rosaria Salerno4, Flora Dell'accio4, Sangita Agarwal7, Boris Lams8, Alex West7 and Patrick Gordon9, 1King's College Hospital, Epsom, United Kingdom, 2Guys and St Thomas's Hospital, London, United Kingdom, 3King's College London, London, United Kingdom, 4King's College Hospital, London, United Kingdom, 5King's College Hospital, London, United Kingdom, 6University Hospital Lewisham, London, United Kingdom, 7Guy's and St Thomas' Hopsital, London, United Kingdom, 8Guys and St Thomas' Hospital, London, 9nhs, London, United Kingdom

    Background/Purpose: ILD is associated with poor survival in patients with idiopathic inflammatory myopathies (IIM). Cyclophosphamide is often used in the management of myositis associated ILD…
  • Abstract Number: 2164 • ACR Convergence 2024

    Boosting Adherence to “Sick Day Rules”: A Quality Improvement Study in Rheumatology Outpatients on Immunosuppressive Medications, Results of Post-intervention Phase

    Merve Aksoy*, Pamela Gonzalez Manrique, Heinrich-Karl Greenblatt and Katarzyna Gilek-Seibert, Roger Williams Medical Center, Providence, RI

    Background/Purpose: Acute infections are common among rheumatology outpatients receiving immunosuppressive medications (IS). Expert guidance advises pausing IS during acute infection, resuming only when clinically improved,…
  • Abstract Number: 2394 • ACR Convergence 2024

    Perioperative Stress Dose vs Therapeutic Dose Comparison: One-Month Postoperative Outcomes in Moderate and Major Surgeries for Systemic Lupus Erythematous and Rheumatoid Arthritis

    Diana Gavilanes1, Alex Jakubiak2, Jhon. F Martinez3 and Anas Atrash4, 1UPMC Health Plan - Harrisburg Pa, Harrisburg, PA, 2Drexel University, Philadelphia, PA, 3BaylorScott&White Health, Waco, TX, 4UPMC Health Plan - Harrisburg Pa, Harrisburg, PA

    Background/Purpose: Major and moderate surgeries are more common in patients with autoimmune diseases. However, there is limited data available regarding the use of standard doses…
  • Abstract Number: 2576 • ACR Convergence 2024

    Glucagon-Like Peptide-1 Receptor Agonist Use and the Risk of Adverse Cardiac and Kidney Outcomes Among Patients with Systemic Lupus Erythematosus and Lupus Nephritis

    April Jorge1, Aakash Patel1, Baijun Zhou2, Yuqing Zhang3 and Hyon K. Choi4, 1Massachusetts General Hospital, Harvard Medical School, Boston, MA, 2Massachusetts General Hospital, Boston, MA, 3Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School; The Mongan Institute, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 4Massachusetts General Hospital, Lexington, MA

    Background/Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are hypoglycemic agents with well-established cardioprotective properties and emerging data for kidney-protective benefits in patients with type 2 diabetes…
  • Abstract Number: 0250 • ACR Convergence 2024

    Effectiveness of Tuberculosis Preventive Treatment in Patients with Rheumatic Diseases: A Global Meta-analysis of Cohort Studies

    Beiming Wang1, Shi Chen2, Xiaoqing Liu3 and Lifan Zhang3, 1Medical Doctor Program, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 2Division of Infectious Diseases, Department of Internal medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 3Peking union medical college hospital, Beijing, China

    Background/Purpose: As patients with rheumatic diseases (RDs) growing into a large population globally, concerns continue exist regarding the potential development of tuberculosis (TB) in this…
  • Abstract Number: 0501 • ACR Convergence 2024

    How Fast Do JAK-inhibitors, TNF-inhibitors, Abatacept and IL-6 Inhibitors Act in Rheumatoid Arthritis? An International Collaboration of Registers of Rheumatoid Arthritis Patients (the “JAK-pot” Study)

    Delphine Sophie Courvoisier1, Yacine Mrad1, Denis Mongin1, Romain Aymon2, Roberto Caporali3, Denis Choquette4, Catalin Codreanu5, Louis Coupal4, Doreen Huschek6, Kimme Hyrich7, Florenzo Iannone8, Tore K. Kvien9, Monika Mustak10, Dan Nordstrom11, Nina Trokovic12, Lucia Otero-Varela13, Karel Pavelka14, Manuel Enrique Pombo Suarez15, Sella A. Provan16, Ana Maria Rodrigues17, Ziga Rotar18, Prodromos Sidiropoulos19, Anja Strangfeld20, Jakub Závada14, Sizheng Zhao21, Axel Finckh1 and Kim Lauper1, 1Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland, 2Division of Rheumatology, Geneva University Hospitals, Collonges-sous-Salève, France, 3Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, 4Rhumadata™, Montreal, QC, Canada, 5University of Medicine and Pharmacy, Bucharest, Romania, 6German Rheumatism Research Center (DRFZ) Berlin, Berlin, Germany, 7Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, 8Rheumatology Unit- University of Bari "Aldo Moro", IT, Bari, Italy, 9Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 10Department of Internal Medicine II, Kaiser Franz Josef Hospital, Vienna, Austria, 11Helsinki University Hospital, Helsinki, Finland, 12Department of Medicine and Rheumatology ROB-FIN, Helsinki University Hospital, Helsinki, Finland, 13Spanish Society of Rheumatology, Madrid, Spain, 14Institute of Rheumatology and Charles University, Praha, Czech Republic, 15Rheumatology Department, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain, 16Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, 17Nova Medical School and Hospital dos Lusíadas, Lisbon, Portugal, 18University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, 19University of Crete, Laboratory of Rheumatology, Autoimmunity and Inflammation. University Hospital, Rheumatology, Clinical Immunology. Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology, Heraklion, Greece, HERAKLIO, Greece, 20German Rheumatism Research Center (DRFZ) Berlin and Charité University Medicine, Berlin, Germany, 21Centre for Musculoskeletal Research, The University of Manchester, Liverpool, United Kingdom

    Background/Purpose: JAK-inhibitors (JAKi) have demonstrated a rapid onset of action; however, it is unclear how they compare to other targeted therapies in rheumatoid arthritis (RA).…
  • Abstract Number: 0603 • ACR Convergence 2024

    Superior Effectiveness and Comparable Drug Retention of Anti-TNF Therapy versus Anti-IL-17A in Ankylosing Spondylitis After First Anti-TNF Failure: A Propensity Score-Matched Analysis from the Czech ATTRA Registry

    Jakub Závada1, Jana Baranová2, Karel Pavelka1, Jiří Vencovský3, Pavel Horak4, Kateřina Kusalová2 and Ladislav Šenolt3, and collaborators of the ATTRA registry, 1Institute of Rheumatology and Charles University, Praha, Czech Republic, 2Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic, 3Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 43rd Department of Internal Medicine - Nephrology, Rheumatology and Endocrinology, University Hospital Olomouc & Palacky University Olomouc, Faculty of Medicine and Dentistry, Olomouc, Olomoucky kraj, Czech Republic

    Background/Purpose: This study aims to compare the drug survival, effectiveness, and safety of anti-IL-17A and anti-TNF drugs in patients with Ankylosing Spondylitis (AS) following the…
  • Abstract Number: 0669 • ACR Convergence 2024

    Efficacy of Belimumab in Systemic Lupus Erythematosus: A Single-Centre Retrospective Study

    buddhika Jayaratna1, Pasan Serasinghe2, Louise Nel3, Sahil Jain3, Shrish Sangle2, Begona Lopez1, Giovanni Sanna2, Michelle Fernando1 and David DCruz4, 1Guys & St Thomas NHS Foundation Trust, London, United Kingdom, 2Guys & St Thomas NHS Foundation Trust, London, England, United Kingdom, 3Guys and St Thomas' Hospital, London, United Kingdom, 4The Louise Coote Lupus Unit, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, United Kingdom

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic multi-system autoimmune rheumatic disorder. Despite therapeutic advances, managing SLE remains challenging due to its complex pathogenesis and…
  • Abstract Number: 0748 • ACR Convergence 2024

    Effectiveness of Interleukin-6 Receptor Inhibitors versus Conventional Synthetic Immunomodulatory Therapy for Treatment of Frail Patients with Polymyalgia Rheumatica

    Sebastian E. Sattui1, Christian Dejaco2, Kerri Ford3, Stefano Fiore4, Sebastian Unizony5, Fenglong Xie6 and Jeffrey Curtis7, 1University of Pittsburgh, Pittsburgh, PA, 2Rheumatology, Hospital of Bruneck (ASAA-SABES), Teaching Hospital of the Paracelsius Medical University, Brunico, Italy, 3Sanofi, Cambridge, MA, 4Sanofi, Bridgewater, NJ, 5Massachusetts General Hospital, Winchester, MA, 6University of Alabama at Birmingham, Birmingham, AL, 7The University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Treatment of polymyalgia rheumatica (PMR) is hindered by lack of glucocorticoid (GC)-sparing therapies with proven efficacy. A retrospective study showed a higher proportion of…
  • Abstract Number: 1193 • ACR Convergence 2024

    Ultrasound-Guided Corticosteroid Injection versus Iontophoresis in Rhizarthrosis: A Prospective Comparative Multicentric Study

    Olga Rusinovich1, Andrea Liso Andrino2, Maria Concepcion Sanchez3, Pilar Navarro Alonso4, Miguel Cantalejo Moreira5, ALBERTO DIAZ OCA4, Pablo Navarro Palomo6, Maria Machattou7, Maria Alonso de Francisco3, Carlota Navarro Joven8, Alejandro Martinez Rodado3, laura Ramos Ortiz de Zarate9, hildegarda Godoy Tundidor10, Maria Carmen Barbadillo Mateos7, Blanca Garcia-Magallon7, Jose Campos7, Mónica Fernández Castro11, JESUS SANZ SANZ6 and Jose Luis Andreu6, 1Hospital Universitario Puerta de Hierro Majadahonda., Boadilla del Monte, Spain, 2Servicio de Reumatología, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , Madrid, Majadahonda, Madrid, Spain, 3Puerta de Hierro Majadahonda University Hospital, Majadahonda, Spain, 4Fuenlabrada University Hospital, Fuenlabrada, Spain, 5Hospital Universitario de Fuenlabrada, Fuenlabrada. Madrid, Spain, 6Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda, Spain, 7Hospital Universitario Puerta de Hierro Majadahonda., Madrid, Spain, 8Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain, 9Puerta de Hierro Majadahonda University Hospital, Majahonda, Spain, 10Servicio de Reumatología, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , Madrid, Madrid, Spain, 11Hospital Universitario Puerta de Hierro Majadahonda., Madrid, Madrid, Spain

    Background/Purpose: Trapeziometacarpal osteoarthritis is a common degenerative disease that causes pain and thumb dysfunction. It affects 16-25% of the population, mainly middle-aged women.  Treatment modalities…
  • Abstract Number: 1306 • ACR Convergence 2024

    A Comparative Analysis of ChatGPT-4, Microsoft’s Bing and Google’s Bard at Answering Rheumatology Clinical Questions

    Pitchaporn Yingchoncharoen1, Nattanicha Chaisrimaneepan2, watsachon Pangkanon1 and Jerapas Thongpiya1, 1Texas Tech Health Sciences Center, Lubbock, TX, 2Texas Tech University Health Sciences Center, Lubbock, TX

    Background/Purpose: The role of artificial intelligence (AI) is rapidly expanding in medical fields, with an increased frequency of use by both patients and providers. There…
  • Abstract Number: 1362 • ACR Convergence 2024

    Comparative Effectiveness of Upadacitinib versus Other JAK Inhibitors in Patients with Rheumatoid Arthritis in a Global Real-World Setting

    Peter C. Taylor1, Aditi Kadakia2, Jack Milligan3, Sander Strengholt2, Oliver Howell3, Pankaj Patel2, Sophie Barlow3 and Roberto Caporali4, 1University of Oxford, Oxford, United Kingdom, 2AbbVie Inc., North Chicago, IL, 3Adelphi Real World, Bollington, United Kingdom, 4Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy

    Background/Purpose: Network meta-analyses of phase 3 clinical trial data involving JAK inhibitor (JAKi)-treated patients with RA and an inadequate response to conventional synthetic DMARDs showed…
  • Abstract Number: 1534 • ACR Convergence 2024

    Use and Safety of Sodium-Glucose Cotransporter-2 Inhibitors Among Patients with Lupus Nephritis and Clinical Indications

    April Jorge1, Kila Panchot2, Baijun Zhou2, Aakash Patel1 and Hyon K. Choi3, 1Massachusetts General Hospital, Harvard Medical School, Boston, MA, 2Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital, Lexington, MA

    Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have nephroprotective and cardioprotective benefits and may have a role in lupus nephritis (LN) treatment. 2023 EULAR SLE treatment guidelines…
  • Abstract Number: 2021 • ACR Convergence 2024

    The Dual Benefits of Sodium-Glucose Cotransporter-2 Inhibitors for Recurrent Nephrolithiasis and Gout Flares Among Gout Patients with Type 2 Diabetes: New User, Active Comparator Target Trial Emulation Studies

    Natalie McCormick1, Chio Yokose2, Leo Lu3, Deborah Wexler1, J. Antonio Avina-Zubieta4, Mary A. De Vera5, saiajay chigurupati1, Kiara Tan1, Chixiang Chen6, Rozalina McCoy6, Gary Curhan7 and Hyon K. Choi8, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Waltham, MA, 3Arthritis Research Canada, Vancouver, BC, Canada, 4Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, 5University of British Columbia, Faculty of Pharmaceutical Sciences, Vancouver, BC, Canada, 6University of Maryland, School of Medicine, Baltimore, MD, 7Brigham and Women's Hospital, Boston, MA, 8Massachusetts General Hospital, Lexington, MA

    Background/Purpose: Nephrolithiasis and gout are both common, extremely painful conditions which frequently coexist, along with type 2 diabetes (T2D). Sodium-glucose cotransporter-2 inhibitors (SGLT2i), first approved…
  • 1
  • 2
  • 3
  • …
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology